A0,A0.35_Verb,A1,A2,Polarity,RelatedSentence
investor William Ackman,say.01,executive has,,Affirmative,( Reuters ) - Activist investor William Ackman said on Monday that Allergan Inc 's chief executive has a disabling conflict of interest because accepting a takeover by Valeant Pharmaceuticals International likely means he would lose his job . 
chief executive,have.03,a disabling conflict of interest,,Affirmative,( Reuters ) - Activist investor William Ackman said on Monday that Allergan Inc 's chief executive has a disabling conflict of interest because accepting a takeover by Valeant Pharmaceuticals International likely means he would lose his job . 
accepting,mean.01,he would lose,,Affirmative,( Reuters ) - Activist investor William Ackman said on Monday that Allergan Inc 's chief executive has a disabling conflict of interest because accepting a takeover by Valeant Pharmaceuticals International likely means he would lose his job . 
Activist investor William Ackman,lose.03,his job,,Affirmative,( Reuters ) - Activist investor William Ackman said on Monday that Allergan Inc 's chief executive has a disabling conflict of interest because accepting a takeover by Valeant Pharmaceuticals International likely means he would lose his job . 
Ackman and,launch.01,takeover of,,Affirmative,"Ackman and Montreal - based Valeant launched a $ 47 billion ( 27.9 billion pounds ) takeover of the company on April 22 , but Allergan rejected the offer on May 12 and has not budged since . "
Allergan 's,reject.01,the offer,,Affirmative,"Ackman and Montreal - based Valeant launched a $ 47 billion ( 27.9 billion pounds ) takeover of the company on April 22 , but Allergan rejected the offer on May 12 and has not budged since . "
Officer David Pyott,urge.01,its shareholders,to let,Affirmative,Allergan Chief Executive Officer David Pyott is urging shareholders to let the company stand alone . 
its shareholders,let.01,company stand alone,,Affirmative,Allergan Chief Executive Officer David Pyott is urging shareholders to let the company stand alone . 
Valeant,say.01,it intended,,Affirmative,"Valeant , however , said last week it intended to sweeten its offer and would discuss the matter in a May 28 webcast . "
last week,intend.01,to sweeten,,Affirmative,"Valeant , however , said last week it intended to sweeten its offer and would discuss the matter in a May 28 webcast . "
last week,sweeten.02,the offer,,Affirmative,"Valeant , however , said last week it intended to sweeten its offer and would discuss the matter in a May 28 webcast . "
last week,discuss.01,the matter,,Affirmative,"Valeant , however , said last week it intended to sweeten its offer and would discuss the matter in a May 28 webcast . "
"Ackman ,",control.01,percent stake in Allergan,,Affirmative,"Ackman , who controls a nearly 10 percent stake in Allergan as the head of Pershing Square Capital Management , criticized Allergan 's position in a May 19 letter to its lead director , Michael Gallagher . "
"Ackman ,",criticize.01,position in,,Affirmative,"Ackman , who controls a nearly 10 percent stake in Allergan as the head of Pershing Square Capital Management , criticized Allergan 's position in a May 19 letter to its lead director , Michael Gallagher . "
The activist investor,say.01,needed,,Affirmative,"The activist investor said Allergan 's board of directors needed to communicate directly with shareholders through the creation of a subcommittee of directors , and he complained that his attempts to speak to the company 's top director without management present were rejected . "
board of directors,need.01,to communicate directly with shareholders,,Affirmative,"The activist investor said Allergan 's board of directors needed to communicate directly with shareholders through the creation of a subcommittee of directors , and he complained that his attempts to speak to the company 's top director without management present were rejected . "
The activist investor,complain.01,were rejected,,Affirmative,"The activist investor said Allergan 's board of directors needed to communicate directly with shareholders through the creation of a subcommittee of directors , and he complained that his attempts to speak to the company 's top director without management present were rejected . "
The activist investor,say.01,are,,Affirmative,"The board 's apparent unwillingness to speak or meet with us and your unwillingness to speak with the company 's largest shareholder without Mr. Pyott present are both material failures of Allergan 's corporate governance at a critical time for Allergan and its shareholders , he said in the letter . "
Allergan Chief Executive Officer David Pyott,have.03,a disabling conflict of interest,,Affirmative,"CEO David Pyott has a disabling conflict of interest that arises from the fact that he will lose his leadership role at the company and likely his job as a result of the transaction , Ackman said in the letter . "
Allergan Chief Executive Officer David Pyott,lose.03,his leadership role,,Affirmative,"CEO David Pyott has a disabling conflict of interest that arises from the fact that he will lose his leadership role at the company and likely his job as a result of the transaction , Ackman said in the letter . "
Activist investor William Ackman,say.01,Pyott has,,Affirmative,"CEO David Pyott has a disabling conflict of interest that arises from the fact that he will lose his leadership role at the company and likely his job as a result of the transaction , Ackman said in the letter . "
Allergan 's,reiterate.01,offer was,,Affirmative,Allergan reiterated on Monday that the takeover offer was too risky for shareholders and it defended its communications with shareholders . 
Allergan 's,defend.01,its communications with shareholders,,Affirmative,Allergan reiterated on Monday that the takeover offer was too risky for shareholders and it defended its communications with shareholders . 
Allergan 's,address.02,the issue of,,Affirmative,It did not address the issue of Pyott possibly having a conflict of interest . 
Allergan Chief Executive Officer David Pyott,have.03,a conflict of interest,,Affirmative,It did not address the issue of Pyott possibly having a conflict of interest . 
Allergan 's,maintain.01,an open line of communication with stockholders,,Affirmative,Allergan maintains an open line of communication with stockholders and welcomes their feedback . 
Allergan 's,welcome.01,their feedback,,Affirmative,Allergan maintains an open line of communication with stockholders and welcomes their feedback . 
its shareholders,believe.01,are not aligned with those of,,Affirmative,"However , as a co-bidder with Valeant Pharmaceuticals , we believe that Mr. Ackman 's views and interests are not aligned with those of other Allergan stockholders , Allergan spokeswoman Bonnie Jacobs said in a statement . "
spokeswoman Bonnie Jacobs,say.01,", we believe",,Affirmative,"However , as a co-bidder with Valeant Pharmaceuticals , we believe that Mr. Ackman 's views and interests are not aligned with those of other Allergan stockholders , Allergan spokeswoman Bonnie Jacobs said in a statement . "
Activist investor William Ackman,say.01,he would call,,Affirmative,He said last week he would call an unofficial Allergan shareholder meeting and a vote on support for the deal . 
Activist investor William Ackman,call.01,an unofficial Allergan shareholder meeting and,,Affirmative,He said last week he would call an unofficial Allergan shareholder meeting and a vote on support for the deal . 
analyst David Maris,say.01,letter is,,Affirmative,"To me the letter is a very old school public pressure type of approach , BMO Capital Markets analyst David Maris said . "
Allergan 's,agree.01,to,,Affirmative,Why would Allergan agree to any further discussions when Valeant has already said they are going to come out with a new bid on the 28th ? 
Valeant,say.01,they are going,,Affirmative,Why would Allergan agree to any further discussions when Valeant has already said they are going to come out with a new bid on the 28th ? 
We,welcome.01,comments on,,Affirmative,We welcome comments on our articles for a limited period after their publication . 
